SciSparc
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 3
- Market Cap
- -
- Website
- http://www.scisparc.com
- Introduction
SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.
Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)
- Conditions
- Autism Spectrum Disorder (ASD)
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- SciSparc
- Target Recruit Count
- 60
- Registration Number
- NCT05182697
- Locations
- 🇮🇱
Clinical Research Center and Negev Autism Center Soroka University Medical Center, Be'er-Sheva, Israel, Be'er-Sheva, Israel
A Phase IIb Study to Determine the Safety, Tolerability and Efficacy of a Daily Oral Dose of SCI-110 in Adult Patients with Tourette's Syndrome (TS)
- Conditions
- Tourette's syndrome in adults (≥18 and ≤65 years) in out-patient care
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Scisparc Ltd.
- Target Recruit Count
- 56
- Registration Number
- 2024-512949-17-00
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Hanover, Germany
A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome
- Conditions
- Tourette Syndrome
- Interventions
- Drug: PlaceboDrug: THX-110 (dronabinol plus PEA)
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- SciSparc
- Target Recruit Count
- 60
- Registration Number
- NCT03651726
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Hannover, Germany
🇩🇪LMU Klinikum der Universität München, Klinik für Psychiatrie und Psychotherapie, Munich, Germany
A Study to Examine the Efficacy of a Therapeutic THX-110 for Obstructive Sleep Apnea
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- SciSparc
- Target Recruit Count
- 30
- Registration Number
- NCT03646552
- Locations
- 🇮🇱
Assuta HaShalom, Tel Aviv, Israel
News
Clearmind Medicine's Psychedelic Combination Treatment for Cocaine Addiction Receives Patent Publication in South Korea
Clearmind Medicine announced the publication of a patent by the Korean Intellectual Property Office for its innovative MEAI and N-Acylethanolamines combination therapy targeting cocaine addiction.
SciSparc's SCI-210 Receives Approval Renewal for Autism Spectrum Disorder Clinical Trial
SciSparc Ltd. has received renewed approval from the Israeli Medical Cannabis Agency for its clinical trial of SCI-210 in children with autism spectrum disorder (ASD).
SciSparc Advances Pharma Portfolio Spin-Off with Miza Ventures, Valued at $11.6 Million
SciSparc has amended its agreement with Miza Ventures to spin off its pharmaceutical portfolio, valuing the assets at approximately $11.6 million.
SciSparc Advances Cannabinoid-Based Therapies for CNS Disorders, Including Autism
SciSparc has enrolled the first patient in its clinical trial for SCI-210, a cannabinoid-based treatment for Autism Spectrum Disorder (ASD) in children.
SciSparc's SCI-110 Receives FDA Clearance for Phase IIb Tourette's Syndrome Trial
SciSparc's SCI-110 receives FDA approval to proceed with Phase IIb clinical trials for Tourette Syndrome treatment, marking a key advancement for the company.